- Home
- SOR vs AMRN Comparison
SOR vs AMRN Comparison
Compare SOR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOR | AMRN |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.4M | 342.8M |
| IPO Year | 1995 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SOR | AMRN |
|---|---|---|
| Price | $46.07 | $14.89 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 10.9K | ★ 83.3K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $41.98 | $12.96 |
| 52 Week High | $50.41 | $20.90 |
Technical Indicators
Market Signals| Indicator | SOR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 41.75 |
| Support Level | $44.85 | $14.76 |
| Resistance Level | $46.76 | $15.09 |
| Average True Range (ATR) | 0.73 | 0.80 |
| MACD | 0.10 | -0.17 |
| Stochastic Oscillator | 85.87 | 9.43 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.